Iridium(III) NHC Complexes for Stable Photodynamic Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current iridium-based photodynamic agents for cancer treatment suffer from instability, limited absorption at long wavelengths, and inefficient singlet oxygen generation, which limits their effectiveness in deep tissue penetration and localized cytotoxicity.
Innovation Solution
Development of iridium(III) complexes with N-heterocyclic carbene ligands that exhibit enhanced stability, strong light absorption in the visible and red regions, and potent singlet oxygen generation capacity, allowing for both dark and light-induced cytotoxicity against cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bidentate cyclometalated ligands and diimine ligands are used in iridium-based photodynamic agents, then the complexes can be synthesized, but they exhibit chemical and photochemical instability
Solution Approach 1:
The patent changes the ligand type from bidentate cyclometalated/diimine ligands to N-heterocyclic carbene (NHC) ligands, fundamentally altering the chemical parameters of the complex to achieve superior stability while maintaining synthetic feasibility through established NHC coordination chemistry
Solution Approach 2:
The patent creates composite iridium complexes combining NHC ligands with porphyrin or phthalocyanine cores, integrating the stability benefits of NHC coordination with the photophysical properties of macrocyclic ligands to achieve both stability and functionality
2Illumination intensity
If iridium chelates are designed for long wavelength absorption, then deep tissue penetration is improved, but the number of available compounds with considerable absorption is limited
Solution Approach 1:
The patent employs universal NHC ligand platforms that can be systematically modified with different porphyrin or phthalocyanine cores, creating a versatile family of compounds that all exhibit long wavelength absorption while maintaining common stabilizing features
Solution Approach 2:
The patent segments the complex into distinct functional modules: a stable NHC-containing iridium center combined with light-absorbing porphyrin/phthalocyanine units, allowing independent optimization of stability and optical properties through modular design
3Reliability
If conventional iridium photodynamic agents are used, then they can treat cancer, but they exhibit inefficient singlet oxygen generation and limited localized cytotoxicity
Solution Approach 1:
The patent optimizes the electronic parameters of the iridium complex by introducing NHC ligands with strong sigma-donor properties, which enhance the triplet excited state character and improve singlet oxygen generation quantum yields to therapeutically effective levels
Solution Approach 2:
The patent converts the typically harmful reactive oxygen species generation into a beneficial localized cytotoxic effect by using NHC-stabilized iridium complexes that generate singlet oxygen specifically at the tumor site upon light activation, achieving targeted therapy with minimal off-target effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The iridium(III)-NHC complexes demonstrate potent cytotoxicity and anti-tumor activity, with enhanced efficacy under light irradiation, achieving significant tumor reduction and localized cytotoxicity while maintaining stability in aqueous solutions.
Implementation Method 1
efficient photochemical singlet oxygen generation are important features for the therapeutic compounds
Implementation Method 2
a method of detecting the Iridium (III) complexes containing N-heterocyclic carbene ligand by fluorescence microscopy
Data Source
AI summary
Provided herein are Ir(III) complexes comprising N-heterocyclic carbene ligand, method of synthesis of the Ir(III) complexes, a pharmaceutical composition comprises thereof. Also provided herein are the methods for the treatment and prevention of cancer/tumor in patients in need thereof by the administration of the Ir(III) complexes under both dark and light conditions. Also provided is a method of detecting the Ir(III) complex in a biological system. Also provided is a method of making the Ir(III) complex. The Ir(III) complexes possess anticancer activity such as the induction of cell death, inhibition of cellular proliferation, and inhibition of tumor growth in vivo.